Cargando…

Impact of Previous Coronavirus Disease 2019 on Immune Response After a Single Dose of BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

Immune response after a single dose of BNT162b2 vaccine was markedly increased in subjects with previous severe acute respiratory syndrome coronavirus 2 infection, reaching similar immunoglobulin titers to those elicited by the full 2 doses in naive cases, and increased modestly after the second dos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Velasco, María, Galán, Maria Isabel, Casas, Maria Luisa, Pérez-Fernández, Elia, Martínez-Ponce, Diana, González-Piñeiro, Beatriz, Castilla, Virgilio, Guijarro, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244747/ https://www.ncbi.nlm.nih.gov/pubmed/34258322 http://dx.doi.org/10.1093/ofid/ofab299

Ejemplares similares

SARS-CoV-2 new infections among health-care workers after the first dose of the BNT162b2 mRNA COVID-19 vaccine. A hospital-wide cohort study
por: Guijarro, Carlos, et al.
Publicado: (2021)

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
por: Nishiguchi, Yamato, et al.
Publicado: (2021)

Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
por: Kahn, Benjamin, et al.
Publicado: (2021)

Specific antibody response of patients with common variable immunodeficiency to BNT162b2 coronavirus disease 2019 vaccination
por: Abo-helo, Nizar, et al.
Publicado: (2021)

Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors
por: Ballman, Madison, et al.
Publicado: (2021)

Incidence of Disease Flare After BNT162b2 Coronavirus Disease 2019 Vaccination in Patients With Rheumatoid Arthritis in Remission
por: Bixio, Riccardo, et al.
Publicado: (2021)

Antibody titers among healthcare workers for coronavirus disease 2019 at 6 months after BNT162b2 vaccination
por: Kurashima, Kazuyoshi, et al.
Publicado: (2022)

Evaluation of neutralizing antibodies after vaccine BNT162b2: Preliminary data
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan
por: Izumo, Takehiro, et al.
Publicado: (2021)

Delayed urticaria after BNT162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein
por: Triwatcharikorn, Jidapa, et al.
Publicado: (2022)

Correspondence Regarding “Tolerability of Coronavirus Disease 2019 Vaccines BNT162b2 and mRNA-1273 in Patients With Thymic Epithelial Tumors”
por: Takada, Kazuki, et al.
Publicado: (2021)

Adverse Reactions after BNT162b2 Messenger RNA Vaccination for Coronavirus Disease 2019 in Healthcare Workers Compared with Influenza Vaccination
por: Kim, A-Sol, et al.
Publicado: (2023)

Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis
por: Ammitzbøll, Christian, et al.
Publicado: (2021)

Specific antibody response of 14 patients with common variable immunodeficiency to 3 BNT162b2 messenger RNA coronavirus disease 2019 vaccinations
por: Abo-Helo, Nizar, et al.
Publicado: (2022)

Association between Vaccination with the BNT162b2 mRNA Coronavirus Disease 2019 Vaccine and Noninfectious Uveitis: A Population-Based Study
por: Tomkins-Netzer, Oren, et al.
Publicado: (2022)

BNT162b2 coronavirus disease-2019 vaccination accelerated rheumatoid arthritis disease activity in chronic eosinophilic pneumonia: A case report
por: Morikawa, Moeko Murano, et al.
Publicado: (2022)

T‐cell response after first dose of BNT162b2 SARS‐CoV‐2 vaccine among healthcare workers with previous infection or cross‐reactive immunity
por: Casado, Jose L, et al.
Publicado: (2021)

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
por: Peeters, M., et al.
Publicado: (2021)

The clinical course of patients with previous acute and recurrent pericarditis receiving the BNT162b2 vaccine
por: Wasserstrum, Yishay, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccination During Pregnancy in Preventing Hospitalization for Severe Acute Respiratory Syndrome Coronavirus 2 in Infants
por: Danino, Dana, et al.
Publicado: (2023)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody kinetics after BNT162B2 vaccination
por: Hettiarachchi, Ravin, et al.
Publicado: (2022)

Perinatally Human Immunodeficiency Virus–Infected Adolescents and Young Adults Demonstrate Distinct BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Immunogenicity( )
por: Morrocchi, Elena, et al.
Publicado: (2022)

Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
por: Naveed, Zaeema, et al.
Publicado: (2022)

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
por: Prendecki, Maria, et al.
Publicado: (2021)

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
por: Manisty, Charlotte, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals
por: Muena, Nicolás A., et al.
Publicado: (2022)

Acquired Thrombotic Thrombocytopenic Purpura Following BNT162b2 mRNA Coronavirus Disease Vaccination in a Japanese Patient
por: Yoshida, Kikuaki, et al.
Publicado: (2021)

Hospital-Wide SARS-CoV-2 seroprevalence in health care workers in a Spanish teaching hospital
por: Galán, Mª Isabel, et al.
Publicado: (2022)

Hospital-Wide SARS-CoV-2 seroprevalence in health care workers in a Spanish teaching hospital
por: Galán, Mª Isabel, et al.
Publicado: (2022)

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
por: Ebinger, Joseph E., et al.
Publicado: (2021)

Quantification and Progress Over Time of Specific Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 in Breast Milk of Lactating Women Vaccinated With BNT162b2 Pfizer-BioNTech Coronavirus Disease 2019 Vaccine (LacCOVID)
por: Esteve-Palau, Erika, et al.
Publicado: (2022)

Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2
por: Siracusano, Gabriel, et al.
Publicado: (2022)

Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study
por: Kang, Yu Min, et al.
Publicado: (2021)

Coronavirus spike protein-specific antibodies indicate frequent infections and reinfections in infancy and among BNT162b2-vaccinated healthcare workers
por: Kolehmainen, Pekka, et al.
Publicado: (2023)

Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2
por: Salvaggio, Marcello, et al.
Publicado: (2021)

Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations
por: Perkmann, Thomas, et al.
Publicado: (2023)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

Anti–severe acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination
por: Kelly, Jeannie C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0fv50cn7nfo9c13heful72ndt0